In this articleJNJFollow your favorite stocksCREATE FREE ACCOUNTAn entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August 28, 2019.Mark Ralston | AFP | Getty ImagesJohnson & Johnson on Tuesday reported first-quarter adjusted earnings that topped Wall Street’s expectations as sales in its medical devices business surged.Meanwhile, the company’s total revenue for the period was largely in line with estimates.J&J’s medtech division provides devices for surgeries, orthopedics and vision. The company is benefiting from a rebound in demand for nonurgent surgeries among older adults, who deferred those procedures during the Covid pandemic. That increased demand has been observed by health insurers like Humana, UnitedHealth Group and Elevance Health.J&J CFO Joseph Wolk told CNBC’s “Squawk Box” on Tuesday that consumers may be pulling back in other areas but “don’t want to compromise when it comes to their health, their mobility, their ability to live a fulfilling life.” He added that the company has seen elevated procedure levels due to Covid, and “we haven’t seen any backtracking of that.”Here’s what J&J reported for the first quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG:Earnings per share: $2.71 adjusted vs. $2.64 expectedRevenue: $21.38 billion vs. $21.4 billion expectedJ&J’s financial results are considered a bellwether for the broader health sector.The company reported $21.38 billion in total sales for the first three months of 2024, up more than 2% from the same quarter in 2023. The pharmaceutical giant booked net income of $5.35 billion, or $2.20 per share during the quarter. That compares with a net loss of $491 million, or 19 cents per share, for the year-earlier period. At the time, J&J recorded costs tied to its talc baby powder liabilities and the spinoff of its consumer health unit Kenvue. Excluding certain items for the first quarter of 2024, adjusted earnings per share were $2.71.J&J also narrowed its full-year guidance for the year. The company now expects sales of $88 billion to $88.4 billion. That compares to a previous forecast of $87.8 billion to $88.6 billion. J&J expects adjusted earnings of $10.57 to $10.72 per share. That compares to a previous guidance of $10.55 to $10.75 per share.Separately on Tuesday, J&J said it will increase its quarterly dividend to $1.24 per share, up 4.2% from $1.19 per share. That marks the company’s 62nd year of consecutive dividend increases, it said. The dividend is payable on June 4.Medical device unitThe results come weeks after J&J’s whopping $13.1 billion acquisition of heart device firm Shockwave Medical — part of its push into the cardiovascular space. Both companies have said the deal will make J&J a leader in four quickly growing cardiovascular technology categories. J&J has scooped up two other heart device companies over the last two years, spending $16.6 billion to buy Abiomed and $400 million to acquire private company Laminar. Those deals also aim to strengthen J&J’s medical devices business following the company’s separation from its consumer health unit Kenvue last year.J&J’s medical devices business generated sales of $7.82 billion during the first quarter, up more than 4% year over year. Wall Street was expecting revenue of $7.87 billion, according to estimates compiled by StreetAccount.J&J said its acquisition of Abiomed fueled the year-over-year rise. The growth also came from electrophysiological products, which evaluate the heart’s electrical system and help doctors understand the cause of abnormal heart rhythms, according to J&J. Wound closure products and devices for orthopedic trauma, or serious injuries of the skeletal or muscular system, contributed, along with contact lenses.Other segmentsMeanwhile, J&J reported $13.56 billion in pharmaceutical sales, marking around 1% year-over-year growth. Excluding sales of its unpopular Covid vaccine, revenue in the pharmaceutical division grew almost 7%.It was the fourth quarter without any U.S. sales from J&J’s Covid vaccine, which brought in $25 million in international revenue.Analysts were expecting sales of $13.5 bi …
Article Attribution | Read More at Article Source
[mwai_chat context=”Let’s have a discussion about this article:nnIn this articleJNJFollow your favorite stocksCREATE FREE ACCOUNTAn entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August 28, 2019.Mark Ralston | AFP | Getty ImagesJohnson & Johnson on Tuesday reported first-quarter adjusted earnings that topped Wall Street’s expectations as sales in its medical devices business surged.Meanwhile, the company’s total revenue for the period was largely in line with estimates.J&J’s medtech division provides devices for surgeries, orthopedics and vision. The company is benefiting from a rebound in demand for nonurgent surgeries among older adults, who deferred those procedures during the Covid pandemic. That increased demand has been observed by health insurers like Humana, UnitedHealth Group and Elevance Health.J&J CFO Joseph Wolk told CNBC’s “Squawk Box” on Tuesday that consumers may be pulling back in other areas but “don’t want to compromise when it comes to their health, their mobility, their ability to live a fulfilling life.” He added that the company has seen elevated procedure levels due to Covid, and “we haven’t seen any backtracking of that.”Here’s what J&J reported for the first quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG:Earnings per share: $2.71 adjusted vs. $2.64 expectedRevenue: $21.38 billion vs. $21.4 billion expectedJ&J’s financial results are considered a bellwether for the broader health sector.The company reported $21.38 billion in total sales for the first three months of 2024, up more than 2% from the same quarter in 2023. The pharmaceutical giant booked net income of $5.35 billion, or $2.20 per share during the quarter. That compares with a net loss of $491 million, or 19 cents per share, for the year-earlier period. At the time, J&J recorded costs tied to its talc baby powder liabilities and the spinoff of its consumer health unit Kenvue. Excluding certain items for the first quarter of 2024, adjusted earnings per share were $2.71.J&J also narrowed its full-year guidance for the year. The company now expects sales of $88 billion to $88.4 billion. That compares to a previous forecast of $87.8 billion to $88.6 billion. J&J expects adjusted earnings of $10.57 to $10.72 per share. That compares to a previous guidance of $10.55 to $10.75 per share.Separately on Tuesday, J&J said it will increase its quarterly dividend to $1.24 per share, up 4.2% from $1.19 per share. That marks the company’s 62nd year of consecutive dividend increases, it said. The dividend is payable on June 4.Medical device unitThe results come weeks after J&J’s whopping $13.1 billion acquisition of heart device firm Shockwave Medical — part of its push into the cardiovascular space. Both companies have said the deal will make J&J a leader in four quickly growing cardiovascular technology categories. J&J has scooped up two other heart device companies over the last two years, spending $16.6 billion to buy Abiomed and $400 million to acquire private company Laminar. Those deals also aim to strengthen J&J’s medical devices business following the company’s separation from its consumer health unit Kenvue last year.J&J’s medical devices business generated sales of $7.82 billion during the first quarter, up more than 4% year over year. Wall Street was expecting revenue of $7.87 billion, according to estimates compiled by StreetAccount.J&J said its acquisition of Abiomed fueled the year-over-year rise. The growth also came from electrophysiological products, which evaluate the heart’s electrical system and help doctors understand the cause of abnormal heart rhythms, according to J&J. Wound closure products and devices for orthopedic trauma, or serious injuries of the skeletal or muscular system, contributed, along with contact lenses.Other segmentsMeanwhile, J&J reported $13.56 billion in pharmaceutical sales, marking around 1% year-over-year growth. Excluding sales of its unpopular Covid vaccine, revenue in the pharmaceutical division grew almost 7%.It was the fourth quarter without any U.S. sales from J&J’s Covid vaccine, which brought in $25 million in international revenue.Analysts were expecting sales of $13.5 bi …nnDiscussion:nn” ai_name=”RocketNews AI: ” start_sentence=”Can I tell you more about this article?” text_input_placeholder=”Type ‘Yes'”]
